Richard William Scalzo
CIK 1789545 · Chief Financial Officer · last filed 2025-12-17
Richard William Scalzo is a Chief Financial Officer who has filed 36 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing, for GLYC, was dated Dec 17, 2025. Across all open-market trades the lifetime net is −$8.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.23M
2
36
-$8.71M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Chief Financial Officer | 19,422 | $15.70 | $304.9K | $0 | 1 | 2025-12-17 |
| DYN | SVP, Head of Finance & Admin. | 122,330 | $18.19 | $2.23M | -$8.71M | 35 | 2025-03-13 |
Recent Filings
36 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-12-17 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | +19,422 | $0 | EDGAR |
| 2025-03-13 | DYN | Sell (S) | −1,343 | -$15.3K | EDGAR |
| 2025-03-07 | DYN | Sell (S) | −917 | -$10.8K | EDGAR |
| 2025-02-18 | DYN | Sell (S) | −2,488 | -$34.7K | EDGAR |
| 2024-12-11 | DYN | Sell (S) | −1,455 | -$40.9K | EDGAR |
| 2024-12-06 | DYN | Grant (A) | +32,700 | $0 | EDGAR |
| 2024-11-18 | DYN | Sell (S) | −2,735 | -$77.1K | EDGAR |
| 2024-09-19 | DYN | Sell (S) | −1,390 | -$48.0K | EDGAR |
| 2024-09-11 | DYN | Sell (S) | −1,468 | -$46.8K | EDGAR |
| 2024-09-10 | DYN | Mixed | −9,596 | -$2.59M | EDGAR |